- Home
- MIN vs AVIR Comparison
MIN vs AVIR Comparison
Compare MIN & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MIN | AVIR |
|---|---|---|
| Founded | 1988 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 298.2M | 236.7M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | MIN | AVIR |
|---|---|---|
| Price | $2.63 | $3.65 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 331.0K | ★ 371.5K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 7.31% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $33.38 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.52 | $2.46 |
| 52 Week High | $2.88 | $4.02 |
Technical Indicators
Market Signals| Indicator | MIN | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 47.87 | 71.27 |
| Support Level | $2.59 | $3.11 |
| Resistance Level | $2.65 | $3.72 |
| Average True Range (ATR) | 0.03 | 0.12 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 43.75 | 90.24 |
Price Performance
Historical ComparisonAbout MIN MFS Intermediate Income Trust
MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises of different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).